Surgery in limited stage small cell lung cancer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Surgery in limited stage small cell lung cancer. / Lassen, U; Hansen, H H.

I: Cancer Treatment Reviews, Bind 25, Nr. 2, 04.1999, s. 67-72.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Lassen, U & Hansen, HH 1999, 'Surgery in limited stage small cell lung cancer', Cancer Treatment Reviews, bind 25, nr. 2, s. 67-72. https://doi.org/10.1053/ctrv.1999.0111

APA

Lassen, U., & Hansen, H. H. (1999). Surgery in limited stage small cell lung cancer. Cancer Treatment Reviews, 25(2), 67-72. https://doi.org/10.1053/ctrv.1999.0111

Vancouver

Lassen U, Hansen HH. Surgery in limited stage small cell lung cancer. Cancer Treatment Reviews. 1999 apr.;25(2):67-72. https://doi.org/10.1053/ctrv.1999.0111

Author

Lassen, U ; Hansen, H H. / Surgery in limited stage small cell lung cancer. I: Cancer Treatment Reviews. 1999 ; Bind 25, Nr. 2. s. 67-72.

Bibtex

@article{8b33a00e11b848229db681d1dfe5a1e9,
title = "Surgery in limited stage small cell lung cancer",
abstract = "The role of surgery in small cell lung cancer (SCLC) is controversial. Surgery has several potential advantages because it may reduce the frequency of local relapses, it does not impede the intensity of chemotherapy, it does not affect the bone marrow, and surgical staging may be of prognostic significance. Several smaller retrospective studies which focus on surgery alone, surgery with adjuvant chemotherapy or radiotherapy, or chemotherapy followed by adjuvant surgery have been reported. Five-year survival data have ranged from 10-50% according to stage, both T-status and nodal status appearing to be significant prognostic factors. Only one prospective randomized trial has been reported concerning the addition of surgery to chemotherapy alone. This trial does not favour surgery. The reason for this could be a selection bias in the smaller non-randomized studies or a result of stage migration. Nevertheless, surgery may yet play an important role in SCLC, especially in diagnosis and staging, and with new improved non-invasive staging procedures, such as positron emission tomography, resection may lead to cure in selected patients. Prospective randomized studies are needed to settle this issue.",
keywords = "Carcinoma, Small Cell, Chemotherapy, Adjuvant, Clinical Trials as Topic, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Neoplasm Staging, Radiotherapy, Adjuvant, Retrospective Studies, Journal Article, Review",
author = "U Lassen and Hansen, {H H}",
note = "Copyright 1999 W.B. Saunders Company Ltd.",
year = "1999",
month = apr,
doi = "10.1053/ctrv.1999.0111",
language = "English",
volume = "25",
pages = "67--72",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B.Saunders Co. Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - Surgery in limited stage small cell lung cancer

AU - Lassen, U

AU - Hansen, H H

N1 - Copyright 1999 W.B. Saunders Company Ltd.

PY - 1999/4

Y1 - 1999/4

N2 - The role of surgery in small cell lung cancer (SCLC) is controversial. Surgery has several potential advantages because it may reduce the frequency of local relapses, it does not impede the intensity of chemotherapy, it does not affect the bone marrow, and surgical staging may be of prognostic significance. Several smaller retrospective studies which focus on surgery alone, surgery with adjuvant chemotherapy or radiotherapy, or chemotherapy followed by adjuvant surgery have been reported. Five-year survival data have ranged from 10-50% according to stage, both T-status and nodal status appearing to be significant prognostic factors. Only one prospective randomized trial has been reported concerning the addition of surgery to chemotherapy alone. This trial does not favour surgery. The reason for this could be a selection bias in the smaller non-randomized studies or a result of stage migration. Nevertheless, surgery may yet play an important role in SCLC, especially in diagnosis and staging, and with new improved non-invasive staging procedures, such as positron emission tomography, resection may lead to cure in selected patients. Prospective randomized studies are needed to settle this issue.

AB - The role of surgery in small cell lung cancer (SCLC) is controversial. Surgery has several potential advantages because it may reduce the frequency of local relapses, it does not impede the intensity of chemotherapy, it does not affect the bone marrow, and surgical staging may be of prognostic significance. Several smaller retrospective studies which focus on surgery alone, surgery with adjuvant chemotherapy or radiotherapy, or chemotherapy followed by adjuvant surgery have been reported. Five-year survival data have ranged from 10-50% according to stage, both T-status and nodal status appearing to be significant prognostic factors. Only one prospective randomized trial has been reported concerning the addition of surgery to chemotherapy alone. This trial does not favour surgery. The reason for this could be a selection bias in the smaller non-randomized studies or a result of stage migration. Nevertheless, surgery may yet play an important role in SCLC, especially in diagnosis and staging, and with new improved non-invasive staging procedures, such as positron emission tomography, resection may lead to cure in selected patients. Prospective randomized studies are needed to settle this issue.

KW - Carcinoma, Small Cell

KW - Chemotherapy, Adjuvant

KW - Clinical Trials as Topic

KW - Humans

KW - Lung Neoplasms

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Radiotherapy, Adjuvant

KW - Retrospective Studies

KW - Journal Article

KW - Review

U2 - 10.1053/ctrv.1999.0111

DO - 10.1053/ctrv.1999.0111

M3 - Journal article

C2 - 10395832

VL - 25

SP - 67

EP - 72

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -

ID: 167432063